Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Revenue (2021 - 2025)

Historic Revenue for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$43292.0.

  • SAB Biotherapeutics' Revenue changed N/A to -$43292.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$62504.0, marking a year-over-year decrease of 10413.19%. This contributed to the annual value of $1.3 million for FY2024, which is 4093.72% down from last year.
  • SAB Biotherapeutics' Revenue amounted to -$43292.0 in Q3 2025.
  • SAB Biotherapeutics' 5-year Revenue high stood at $18.2 million for Q2 2021, and its period low was -$69565.0 during Q1 2025.
  • Moreover, its 5-year median value for Revenue was $1.1 million (2023), whereas its average is $4.9 million.
  • In the last 5 years, SAB Biotherapeutics' Revenue surged by 20769.78% in 2024 and then plummeted by 12445.3% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Revenue (Quarter) stood at $11.1 million in 2021, then crashed by 80.46% to $2.2 million in 2022, then tumbled by 85.88% to $305011.0 in 2023, then plummeted by 62.4% to $114698.0 in 2024, then plummeted by 137.74% to -$43292.0 in 2025.
  • Its Revenue stands at -$43292.0 for Q3 2025, versus -$64345.0 for Q2 2025 and -$69565.0 for Q1 2025.